Medtronic Q3 2026 Earnings

In their **Q3 2026 earnings report**, Medtronic announced **$9 billion in revenue**, representing a significant **8.7% reported increase** and the company's strongest growth in ten quarters. The **Cardiovascular Portfolio** emerged as a primary engine for this success, bolstered by an **80% surge in Cardiac Ablation Solutions** following the expansion of pulsed field ablation technologies. Leadership highlighted several "generational growth drivers," including the **FDA clearance of the Hugo surgical robot** and the **Stealth AXiS system**, alongside strong demand for the **Symplicity Spyral** hypertension treatment. Despite these gains, the company managed **financial headwinds from tariffs** and specific product mix challenges while preparing for the **planned separation of its diabetes business** by late 2026. Medtronic **reiterated its full-year guidance**, expressing confidence that its robust innovation pipeline and strategic acquisitions will sustain **high single-digit earnings growth** into 2027.

Видео Medtronic Q3 2026 Earnings канала Daily Market Download